The roles of metallothioneins in carcinogenesis.
Si M, Lang J. · 2018
Read The roles of metallothioneins in carcinogenesis. by Si M, Lang J. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6108115.txt.
Introduction
Si and Lang wrote a review in Journal of Hematology and Oncology on metallothioneins and cancer. Metallothioneins are small proteins that bind metals in cells. They help guard cells against toxic metals and stress. The review asks how they take part in the start and growth of cancer.
The authors survey work on these proteins across many tumor types. The cited studies link them to tumor growth and patient survival. Others link them to drug resistance and cell death. Some forms seem to slow tumors, while others rise with worse disease. Readers get a map of a protein family with mixed roles in cancer.
Catalog record
| CREATOR | Si M, Lang J. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 99 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The roles of metallothioneins in carcinogenesis By Manfei Si, Jinghe Lang Published in: Journal of Hematology & Oncology DOI: 10.1186/s13045-018-0645-x ABSTRACT Abstract CONTRIBUTOR INFORMATION Manfei Si, Email: [email protected]. Jinghe Lang, Email: [email protected]. REFERENCES 1.Coyle P, Philcox JC, Carey LC, Rofe AM. Metallothionein: the multipurpose protein. Cell Mol Life Sci. 2002;59:627–647. doi: 10.1007/s00018-002-8454-2.2.Albrecht AL, Singh RK, Somji S, Sens MA, Sens DA, Garrett SH. Basal and metal-induced expression of metallothionein isoform 1 and 2 genes in the RWPE-1 human prostate epithelial cell line. J Appl Toxicol. 2008;28:283–293. doi: 10.1002/jat.1277.3.Margoshes M, Vallee BL. A cadmium protein from equine kidney cortex. J Am Chem Soc. 1957;79:4813–4814. doi: 10.1021/ja01574a064.4.Klaassen CD, Liu J, Diwan BA. Metallothionein protection of cadmium toxicity. Toxicol Appl Pharmacol. 2009;238:215–220. doi: 10.1016/j.taap.2009.03.026.5.Kumari MV, Hiramatsu M, Ebadi M. Free radical scavenging actions of metallothionein isoforms I and II. Free Radic Res. 1998;29:93–101. doi: 10.1080/10715769800300111.6.Arriaga JM, Levy EM, Bravo AI, Bayo SM, Amat M, Aris M, Hannois A, Bruno L, Roberti MP, Loria FS, et al. Metallothionein expression in colorectal cancer: relevance of different isoforms for tumor progression and patient survival. Hum Pathol. 2012;43:197–208. doi: 10.1016/j.humpath.2011.04.015.7.Ferrario C, Lavagni P, Gariboldi M, Miranda C, Losa M, Cleris L, Formelli F, Pilotti S, Pierotti MA, Greco A. Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma. Lab Investig. 2008;88:474–481. doi: 10.1038/labinvest.2008.17.8.Zheng Y, Jiang L, Hu Y, Xiao C, Xu N, Zhou J, Zhou X. Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/beta-catenin signaling pathway. BMC Cancer. 2017;17:161. doi: 10.1186/s12885-017-3139-2.9.Pedersen MO, Larsen A, Stoltenberg M, Penkowa M. The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem. 2009;44:29–64. doi: 10.1016/j.proghi.2008.10.001.10.Demidenko R, Daniunaite K, Bakavicius A, Sabaliauskaite R, Skeberdyte A, Petroska D, Laurinavicius A, Jankevicius F, Lazutka JR, Jarmalaite S. Decreased expression of MT1E is a potential biomarker of prostate cancer progression. Oncotarget. 2017;8:61709–61718. doi: 10.18632/oncotarget.18683.11.Vasak M. Advances in metallothionein structure and functions. J Trace Elem Med Biol. 2005;19:13–17. doi: 10.1016/j.jtemb.2005.03.003.12.Thirumoorthy N, Manisenthil Kumar KT, Shyam Sundar A, Panayappan L, Chatterjee M. Metallothionein: an overview. World J Gastroenterol. 2007;13:993–996. doi: 10.3748/wjg.v13.i7.993.13.Moleirinho A, Carneiro J, Matthiesen R, Silva RM, Amorim A, Azevedo L. Gains, losses and changes of function after gene duplication: study of the metallothionein family. PLoS One. 2011;6:e18487. doi: 10.1371/journal.pone.0018487.14.Krzeslak A, Forma E, Chwatko G, Jozwiak P, Szymczyk A, Wilkosz J, Rozanski W, Brys M. Effect of metallothionein 2A gene polymorphism on allele-specific gene expression and metal content in prostate cancer. Toxicol Appl Pharmacol. 2013;268:278–285. doi: 10.1016/j.taap.2013.02.013.15.Ruttkay-Nedecky B, Nejdl L, Gumulec J, Zitka O, Masarik M, Eckschlager T, Stiborova M, Adam V, Kizek R. The role of metallothionein in oxidative stress. Int J Mol Sci. 2013;14:6044–6066. doi: 10.3390/ijms14036044.16.Krezel A, Maret W. The functions of metamorphic metallothioneins in zinc and copper metabolism. Int J Mol Sci. 2017;18(6). 10.3390/ijms18061237.17.Cherian MG, Jayasurya A, Bay BH. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res. 2003;533:201–209. doi: 10.1016/j.mrfmmm.2003.07.013.18.Shimoda R, Achanzar WE, Qu W, Nagamine T, Takagi H, Mori M, Waalkes MP. Metallothionein is a potential negative regulator of apoptosis. Toxicol Sci. 2003;73:294–300. doi: 10.1093/toxsci/kfg095.19.Dutsch-Wicherek M, Sikora J, Tomaszewska R. The possible biological role of metallothionein in apoptosis. Front Biosci. 2008;13:4029–4038. doi: 10.2741/2991.20.Gomulkiewicz A, Podhorska-Okolow M, Szulc R, Smorag Z, Wojnar A, Zabel M, Dziegiel P. Correlation between metallothionein (MT) expression and selected prognostic factors in ductal breast cancers. Folia Histochem Cytobiol. 2010;48:242–248. doi: 10.2478/v10042-010-0011-5.21.Jayasurya A, Bay BH, Yap WM, Tan NG, Tan BK. Proliferative potential in nasopharyngeal carcinoma: correlations with metallothionein expression and tissue zinc levels. Carcinogenesis. 2000;21:1809–1812. doi: 10.1093/carcin/21.10.1809.22.Hengstler JG, Pilch H, Schmidt M, Dahlenburg H, Sagemuller J, Schiffer I, Oesch F, Knapstein PG, Kaina B, Tanner B. Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis. Int J Cancer. 2001;95:121–127. doi: 10.1002/1097-0215(20010320)95:2<121::AID-IJC1021>3.0.CO;2-N.23.Wulfing C, van Ahlen H, Eltze E, Piechota H, Hertle L, Schmid KW. Metallothionein in bladder cancer: correlation of overexpression with poor outcome after chemotherapy. World J Urol. 2007;25:199–205. doi: 10.1007/s00345-006-0141-8.24.Weinlich G, Eisendle K, Hassler E, Baltaci M, Fritsch PO, Zelger B. Metallothionein - overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients. Br J Cancer. 2006;94:835–841. doi: 10.1038/sj.bjc.6603028.25.Datta J, Majumder S, Kutay H, Motiwala T, Frankel W, Costa R, Cha HC, MacDougald OA, Jacob ST, Ghoshal K. Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer Res. 2007;67:2736–2746. doi: 10.1158/0008-5472.CAN-06-4433.26.Han YC, Zheng ZL, Zuo ZH, Yu YP, Chen R, Tseng GC, Nelson JB, Luo JH. Metallothionein 1 h tumour suppressor activity in prostate cancer is mediated by euchromatin methyltransferase 1. J Pathol. 2013;230:184–193. doi: 10.1002/path.4169.27.Theocharis S, Karkantaris C, Philipides T, Agapitos E, Gika A, Margeli A, Kittas C, Koutselinis A. Expression of metallothionein in lung carcinoma: correlation with histological type and grade. Histopathology. 2002;40:143–151. doi: 10.1046/j.1365-2559.2002.01325.x.28.Lee JD, Wu SM, Lu LY, Yang YT, Jeng SY. Cadmium concentration and metallothionein expression in prostate cancer and benign prostatic hyperplasia of humans. J Formos Med Assoc. 2009;108:554–559. doi: 10.1016/S0929-6646(09)60373-9.29.Dziegiel P, Pula B, Kobierzycki C, Stasiolek M, Podhorska-Okolow M. The role of metallothioneins in carcinogenesis. Metallothioneins in Normal and Cancer Cells. 2016. pp. 29–63.30.Uchida Y, Takio K, Titani K, Ihara Y, Tomonaga M. The growth inhibitory factor that is deficient in the Alzheimer’s disease brain is a 68 amino acid metallothionein-like protein. Neuron. 1991;7:337–347. doi: 10.1016/0896-6273(91)90272-2.31.Palmiter RD, Findley SD, Whitmore TE, Durnam DM. MT-III, a brain-specific member of the metallothionein gene family. Proc Natl Acad Sci U S A. 1992;89:6333–6337. doi: 10.1073/pnas.89.14.6333.32.Quaife CJ, Findley SD, Erickson JC, Froelick GJ, Kelly EJ, Zambrowicz BP, Palmiter RD. Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified squamous epithelia. Biochemistry. 1994;33:7250–7259. doi: 10.1021/bi00189a029.33.Haq F, Mahoney M, Koropatnick J. Signaling events for metallothionein induction. Mutat Res. 2003;533:211–226. doi: 10.1016/j.mrfmmm.2003.07.014.34.Krizkova S, Kepinska M, Emri G, Eckschlager T, Stiborova M, Pokorna P, Heger Z, Adam V. An insight into the complex roles of metallothioneins in malignant diseases with emphasis on (sub)isoforms/isoforms and epigenetics phenomena. Pharmacol Ther. 2018;183:90–117. doi: 10.1016/j.pharmthera.2017.10.004.35.Cherian MG, Huang PC, Klaassen CD, Liu YP, Longfellow DG, Waalkes MP. National Cancer Institute Workshop on the possible roles of metallothionein in carcinogenesis. Cancer Res. 1993;53:922–925.36.Nagel WW, Vallee BL. Cell cycle regulation of metallothionein in human colonic cancer cells. Proc Natl Acad Sci U S A. 1995;92:579–583. doi: 10.1073/pnas.92.2.579.37.Chesters JK, Petrie L, Vint H. Specificity and timing of the Zn2+ requirement for DNA synthesis by 3T3 cells. Exp Cell Res. 1989;184:499–508. doi: 10.1016/0014-4827(89)90347-9.38.Chesters JK, Boyne R. Nature of the Zn2+ requirement for DNA synthesis by 3T3 cells. Exp Cell Res. 1991;192:631–634. doi: 10.1016/0014-4827(91)90085-9.39.Lim D, Jocelyn KM, Yip GW, Bay BH. Silencing the metallothionein-2A gene inhibits cell cycle progression from G1- to S-phase involving ATM and cdc25A signaling in breast cancer cells. Cancer Lett. 2009;276:109–117. doi: 10.1016/j.canlet.2008.10.038.40.Werynska B, Pula B, Muszczynska-Bernhard B, Piotrowska A, Jethon A, Podhorska-Okolow M, Dziegiel P, Jankowska R. Correlation between expression of metallothionein and expression of Ki-67 and MCM-2 proliferation markers in non-small cell lung cancer. Anticancer Res. 2011;31:2833–2839.41.Jin RX, Chow VTK, Tan PH, Dheen ST, Duan W, Bay BH. Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis. 2002;23:81–86. doi: 10.1093/carcin/23.1.81.42.Dziegiel P, Forgacz J, Suder E, Surowiak P, Kornafel J, Zabel M. Prognostic significance of metallothionein expression in